Surgery patients were also far more likely to sustain results: 96% maintained at least 10% weight loss , compared to 46% in the GLP-1 group
Decreased plasma peptide YY accompanied by elevated peptide YY and Y2 receptor binding densities in the medulla oblongata of diet-induced obese mice
Severe or non-stop vomiting, or you can't keep fluids down (dehydration) Severe stomach pain, especially if it spreads to your back (possible pancreatitis) Upper-right belly pain, fever, or yellowing skin/eyes (gallbladder) Signs of an allergic reaction swelling, trouble breathing, a spreading rash These are class-wide GLP-1 warnings
These can keep you full for hours and push your next real meal out of reach, which is the opposite of what you want when total intake is already low
[1] The gradual dose escalation protocol is designed specifically to minimise these gastrointestinal symptoms
Minafra, A